Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| AVANIR PHARMACEUTICALS | 914,249 | reported | 17 Dec 2014 | tx 117+5,759,504−3,671,407 |
| Urovant Sciences Ltd. | 379,680 | reported | 19 Feb 2020 | tx 12+1,369,962−420,000 |
| Syndax Pharmaceuticals Inc | 124,000 | reported | 04 Feb 2026 | tx 37+265,000−68,000 |
| Emergent BioSolutions Inc. | 111,775 | reported | 30 Apr 2026 | tx 10+172,487−23,325 |
| RIGEL PHARMACEUTICALS INC | 30,000 | reported | 19 May 2021 | tx 8+365,000 |
| KalVista Pharmaceuticals, Inc. | 29,000 | reported | 03 Aug 2015 | tx 1+29,000 |
| Eledon Pharmaceuticals, Inc. | 8,575 | reported | 10 Jan 2026 | tx 11+957,517.15−8,575 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 30 Apr 2026 | GRANT_AWARD | Emergent BioSolutions Inc. | 25,344 | 0.00 USD | 10b5-1 |
| 30 Apr 2026 | SALE | Emergent BioSolutions Inc. | 15,481 | 8.28 USD | 10b5-1 |
| 30 Apr 2026 | GRANT_AWARD | Emergent BioSolutions Inc. | 11,296 | 0.00 USD | 10b5-1deriv |
| 04 Feb 2026 | GRANT_AWARD | Syndax Pharmaceuticals Inc | 24,000 | 0.00 USD | |
| 10 Jan 2026 | EXERCISE | Eledon Pharmaceuticals, Inc. | 8,575 | 0.00 USD | |
| 10 Jan 2026 | EXERCISE | Eledon Pharmaceuticals, Inc. | 8,575 | 0.00 USD | deriv |
| 23 May 2025 | SALE | Emergent BioSolutions Inc. | 7,844 | 6.30 USD | |
| 19 May 2025 | PURCHASE | Syndax Pharmaceuticals Inc | 10,000 | 9.11 USD | first after silence |
| 30 Apr 2025 | GRANT_AWARD | Emergent BioSolutions Inc. | 34,403 | 0.00 USD | |
| 30 Apr 2025 | GRANT_AWARD | Emergent BioSolutions Inc. | 15,824 | 0.00 USD | deriv |
| 05 Feb 2025 | GRANT_AWARD | Syndax Pharmaceuticals Inc | 25,000 | 0.00 USD | |
| 10 Jan 2025 | GRANT_AWARD | Eledon Pharmaceuticals, Inc. | 8,575 | 0.00 USD | deriv |
| 10 Jan 2025 | GRANT_AWARD | Eledon Pharmaceuticals, Inc. | 77,175 | 0.00 USD | deriv |
| 23 May 2024 | GRANT_AWARD | Emergent BioSolutions Inc. | 17,430 | 0.00 USD | |
| 23 May 2024 | GRANT_AWARD | Emergent BioSolutions Inc. | 25,748 | 0.00 USD | deriv |
| 07 Feb 2024 | GRANT_AWARD | Syndax Pharmaceuticals Inc | 17,000 | 0.00 USD | |
| 25 May 2023 | GRANT_AWARD | Emergent BioSolutions Inc. | 33,847 | 0.00 USD | |
| 01 May 2023 | GRANT_AWARD | Eledon Pharmaceuticals, Inc. | 752,185 | 0.00 USD | deriv |
| 02 Feb 2023 | GRANT_AWARD | Syndax Pharmaceuticals Inc | 16,000 | 0.00 USD | |
| 01 Feb 2023 | GRANT_AWARD | Eledon Pharmaceuticals, Inc. | 20,000 | 0.00 USD | deriv |
| 06 Oct 2022 | EXERCISE | Syndax Pharmaceuticals Inc | 9,117 | 8.93 USD | |
| 06 Oct 2022 | SALE | Syndax Pharmaceuticals Inc | 20,782 | 25.90 USD | |
| 06 Oct 2022 | SALE | Syndax Pharmaceuticals Inc | 9,117 | 25.90 USD | |
| 06 Oct 2022 | EXERCISE | Syndax Pharmaceuticals Inc | 20,782 | 7.88 USD | |
| 06 Oct 2022 | EXERCISE | Syndax Pharmaceuticals Inc | 9,117 | 0.00 USD | deriv |
3 purchases reported after at least 12 months of silence — most recent on 19 May 2025.